FAQ
What You Actually Want to
Know About
Longevity Medicine
Real answers from board-certified physicians.
-
Most men don’t recognize hormonal decline because it happens gradually. The signs are easy to dismiss as stress or aging, but they are often driven by measurable changes in testosterone, thyroid, cortisol, and DHEA.
The most common signs include persistent fatigue that sleep doesn’t fix, loss of muscle mass despite regular exercise, increased body fat around the abdomen, reduced motivation or mental sharpness, lower libido, and slower workout recovery. Many men also notice mood changes: shorter fuse, less drive, a general flatness that doesn’t match their personality.
Standard lab panels from a primary care doctor often miss this. A TSH and a total testosterone number do not tell the full story. At Atlas Lifespan in Pennington, NJ, we run comprehensive hormone panels including free testosterone, SHBG, LH, FSH, estradiol, thyroid function, and metabolic markers. If you are over 40 and performing below your baseline, hormonal optimization is worth evaluating seriously. -
Atlas Lifespan in Pennington, NJ is a physician-led longevity and performance medicine practice founded by Dr. Swara Afiniwala, MD (Internal Medicine) and Dr. Deep Trivedi, MD, MBA (Urology). Both physicians are board-certified and specialize in hormonal optimization, metabolic health, peptide therapy, and evidence-based longevity protocols.
What separates Atlas from wellness clinics and medspas is the clinical foundation. Every protocol is physiciandesigned, lab-driven, and individualized. We do not work from templates. We treat executives, professionals, and high-performing individuals who want to stay ahead of decline, not respond to it.
Atlas offers in-person care at our Pennington, NJ location and telemedicine for patients across the United States. -
Yes. When properly prescribed and monitored by a physician, testosterone replacement therapy is safe and well-supported by the medical literature. The landmark TRAVERSE trial, published in the New England Journal of Medicine, showed that TRT does not increase the risk of major cardiovascular events in men with hypogonadism.
In many cases, the risks of untreated low testosterone are greater, including increased cardiovascular risk, insulin resistance, osteoporosis, cognitive decline, and loss of muscle mass.
TRT is not one-size-fits-all. At Atlas Lifespan, we review each patient’s labs, symptoms, cardiovascular history, and goals before recommending a protocol. Ongoing monitoring including testosterone levels, hematocrit, estradiol, and PSA is built into every TRT program we manage. -
Bioidentical hormone replacement therapy uses hormones that are chemically identical to those your body produces naturally, including estradiol, progesterone, and testosterone, to restore levels that decline with age. This is different from older synthetic hormone formulations, which have different molecular structures and different risk profiles.
Women in perimenopause and menopause are the most common candidates. The Women’s Health Initiative study that caused widespread fear of hormone therapy used synthetic conjugated equine estrogen, not bioidentical estradiol. Subsequent research has consistently shown that bioidentical estradiol, especially transdermal delivery, does not carry the same clot or breast cancer risk.
At Atlas Lifespan, Dr. Swara Afiniwala evaluates women comprehensively across hormones, thyroid, and metabolic markers and designs protocols that address the full picture. -
A conventional physician is trained to identify and treat disease. A longevity physician is trained to identify and correct the slow decline that precedes disease, often years before a diagnosis would be made.
A primary care doctor may look at your TSH and call it normal because it falls within the standard reference range. A longevity physician looks at whether that number is optimal for your age, symptoms, and function, and whether your free T3, reverse T3, and thyroid antibodies tell a different story.
At Atlas Lifespan, every patient starts with a comprehensive baseline assessment. We then build a protocol that may include hormonal optimization, peptide therapy, metabolic support, and lifestyle recommendations. The goal is not to manage aging. It is to change its trajectory. -
Peptides are short chains of amino acids that act as signaling molecules directing processes like growth hormone release, tissue repair, fat metabolism, immune function, and sleep. Peptide therapy uses specific peptides to restore or enhance these signals as they naturally decline with age.
Some of the peptides we use most often at Atlas Lifespan include:- Sermorelin and CJC-1295 with Ipamorelin — growth hormone secretagogues supporting muscle preservation, fat loss, sleep quality, and recovery
- BPC-157 — tissue repair in joints, tendons, gut lining, and the nervous system
- Tirzepatide and Semaglutide — metabolic health, cardiovascular risk, and longevity beyond weight loss
- PT-141 — sexual function in both men and women
At Atlas Lifespan, we prescribe pharmaceutical-grade peptides through licensed compounding pharmacies and monitor all patients on active protocols.
-
GLP-1 receptor agonists affect far more than blood sugar. These medications slow gastric emptying, reduce appetite signaling, improve insulin sensitivity, decrease inflammation, and have demonstrated cardiovascular and neuroprotective effects in clinical trials.
The SELECT trial showed a 20% reduction in major cardiovascular events in patients on semaglutide who were overweight but not diabetic.
At Atlas Lifespan, GLP-1 therapy is part of a broader metabolic optimization protocol combined with nutritional guidance, resistance training support, and often hormonal optimization. The goal is a metabolic reset that changes your long-term health trajectory
-
Most people feel something is off before any lab confirms it. You are sleeping enough but waking up exhausted. You are exercising but not recovering or seeing results. Your mood, libido, or mental sharpness has shifted in a way that feels like more than just stress.
Standard lab ranges were designed to catch disease, not identify suboptimal function. Someone can have a testosterone level that falls inside the normal range and feel terrible.
At Atlas Lifespan, we evaluate symptoms alongside a comprehensive panel. If there is a gap between how you
feel and how you want to feel, that is what our initial consultation is designed to answer. -
Perimenopause can begin as early as the mid-30s, though most women notice it in their early to mid-40s. It can last anywhere from two to ten years before the final menstrual period.
The most common signs include irregular periods, sleep disruption especially waking in the middle of the night, increased anxiety or mood swings that feel out of proportion, brain fog, changes in body composition, decreased libido, and new or worsening joint pain. Estrogen and progesterone fluctuate erratically during perimenopause, which is why symptoms can feel unpredictable from month to month.
At Atlas Lifespan, Dr. Swara Afiniwala specializes in the perimenopausal transition and helps women identify and address hormonal shifts before they become entrenched.
-
Yes, and this is one of the most underappreciated areas in women’s health. Testosterone is not just a male hormone. Women produce it naturally and it plays a critical role in energy, libido, muscle maintenance, cognitive function, mood, and bone density. Testosterone levels in women begin declining in the late 20s, well before estrogen and progesterone shift significantly.
Low testosterone in women often presents as persistent fatigue, loss of motivation, reduced libido, difficulty building or maintaining muscle, and a general sense of mental flatness. These symptoms are frequently dismissed or attributed to depression or stress.
When indicated, testosterone therapy for women is prescribed at much lower doses than for men and typically delivered transdermally. At Atlas Lifespan, testosterone is part of a comprehensive hormonal assessment for women, not an afterthought.
-
Our initial assessment is more comprehensive than a standard panel. For women, this typically includes estradiol, progesterone, total and free testosterone, SHBG, DHEA-S, FSH, LH, a full thyroid panel including TSH, free T3, free T4, reverse T3, and thyroid antibodies, fasting insulin, HbA1c, fasting glucose, a full lipid panel with advanced cardiovascular markers including ApoB and Lp(a), ferritin, vitamin D, magnesium, and a comprehensive metabolic panel.
For men, we add prostate markers and fertility-related hormones where appropriate. Lab work is done through LabCorp. We review results with each patient in full, not just flag abnormals.
-
Atlas Lifespan offers both. Initial consultations and follow-up visits are available via telemedicine for patients across the United States. Lab work can be completed at any LabCorp location near you.
In-person care is available at our Pennington, NJ office at 10 Route 31. Most ongoing care for patients on hormonal or metabolic protocols is managed via telemedicine, which makes it practical for patients with demanding schedules.
-
Most patients notice meaningful changes within four to eight weeks of starting a protocol. Sleep and energy often improve first, sometimes within the first two weeks. Libido and mood typically follow. Body composition changes and metabolic improvements become more apparent at the three to six month mark.
Hormone optimization is not a quick fix. Levels are titrated carefully and most protocols require adjustment over the first few months based on follow-up labs and how you feel. Patients who stay consistent with monitoring see the strongest long-term results.
-
The answer is more nuanced than the blanket “no” that many women hear. The Women’s Health Initiative used oral synthetic progestins combined with conjugated equine estrogen. That combination carries a different risk profile than bioidentical estradiol with micronized progesterone.
Current evidence shows that bioidentical progesterone does not carry the same breast cancer risk as synthetic progestins. For women with a family history but no personal diagnosis or high-risk genetic marker such as BRCA, bioidentical HRT can often be considered after a full risk-benefit discussion.
At Atlas Lifespan, we review each patient’s personal and family history, genetic risk, and current hormonal status before making any recommendation. For some women, the risks of untreated hormonal decline including bone loss, cardiovascular risk, and cognitive decline are significant and deserve to be weighed honestly.
-
No. This is one of the most persistent myths in men’s health, and it has caused significant harm by keeping men with low testosterone from getting treatment they need.
The fear originated from a 1941 study that was taken out of context and applied broadly for decades. Harvard urologist Dr. Abraham Morgentaler developed the Saturation Model showing that prostate androgen receptors become saturated at low testosterone levels around 200 to 250 ng/dL. Once saturated, additional testosterone has no further stimulating effect on prostate tissue.
The TRAVERSE trial published in the New England Journal of Medicine in 2023 followed over 5,000 men with hypogonadism and found no increased incidence of prostate cancer in men receiving testosterone therapy. Multiple meta-analyses including a large analysis in the Annals of Internal Medicine reached the same conclusion. Prostate cancer incidence is actually higher in older men with lower testosterone levels.
At Atlas Lifespan, every man starting TRT has baseline PSA assessment with regular monitoring built into the
protocol. -
These are four brand names referring to two medications. Semaglutide is the active ingredient in both Ozempic (FDA-approved for type 2 diabetes) and Wegovy (FDA-approved for weight management). Tirzepatide is the active ingredient in both Mounjaro (diabetes) and Zepbound (weight management).
The more clinically meaningful distinction is between the two molecules. Tirzepatide is a dual GLP-1 and GIP receptor agonist, activating two pathways instead of one. In head-to-head trials, tirzepatide has generally produced greater weight loss and metabolic improvements than semaglutide.
At Atlas Lifespan, we prescribe both and the choice depends on each patient’s metabolic profile, goals, tolerability, and history. These medications are part of a broader protocol, not standalone prescriptions.
-
Atlas Lifespan operates as a direct-pay practice and does not bill insurance. Insurance reimbursement is built around diagnosing and treating disease. It does not cover optimization, prevention, or the kind of comprehensive lab work and individualized protocol development that longevity medicine requires.
Some patients are able to use HSA or FSA funds for services and lab work. Certain lab panels may also be partially reimbursable depending on your plan. We provide documentation to support reimbursement requests where applicable and are transparent about pricing at the time of consultation.
-
Low testosterone in men and low estrogen in women are independently associated with increased visceral fat, reduced lean muscle mass, and slower metabolic rate. This is not about willpower or effort. It is biology.
Insulin resistance compounds the problem. When cells stop responding effectively to insulin, fat storage increases especially around the abdomen and the body becomes less efficient at using stored fat for energy. Thyroid dysfunction can meaningfully slow metabolism and make weight loss nearly impossible despite caloric restriction. Cortisol elevation drives fat storage in the abdominal area and breaks down muscle tissue.
At Atlas Lifespan, we approach weight that is resistant to conventional effort as a hormonal and metabolic problem first.
-
Menopause is defined as twelve consecutive months without a menstrual period. It is a single point in time, not a phase. The average age in the United States is 51.
Perimenopause is the transition phase leading up to that point, which can begin anywhere from two to ten years before the final period. During perimenopause, estrogen and progesterone fluctuate erratically rather than declining steadily, which is why symptoms can feel inconsistent and confusing from month to month.
Postmenopause refers to all years following the final period. Many women seek care during perimenopause because something clearly feels different even though conventional testing may not yet show a dramatic shift. This is exactly the right time to evaluate. Waiting until full menopause means years of unnecessary symptoms and health consequences that are harder to reverse.
-
Brain fog during the hormonal transition is real and well-documented. Estrogen supports blood flow to the brain, helps regulate neurotransmitters that govern memory and attention, and protects neurons from oxidative damage. When estrogen begins fluctuating during perimenopause, cognitive symptoms often follow.
Sleep disruption compounds the problem significantly. Poor or fragmented sleep alone can produce symptoms clinically indistinguishable from cognitive impairment. Many women dealing with brain fog are also waking repeatedly due to hot flashes or hormonal insomnia.
Research consistently shows that transdermal estradiol improves verbal memory, processing speed, and mental clarity in women during perimenopause and early menopause. Starting hormone therapy within ten years of the final menstrual period or before age 60 appears to carry the most benefit. At Atlas Lifespan, brain fog is one of the most common presenting complaints and hormonal optimization is central to the solution.
-
Yes, menopause-related hair loss is real and common. It is one of the symptoms women are least warned about and most distressed by when it begins.
Estrogen and progesterone support hair growth by prolonging the growth phase of the hair cycle and reducing follicle sensitivity to androgens. When these hormones decline, DHT has more relative effect on follicles, leading to miniaturization of the hair shaft and increased shedding. This typically presents as overall thinning across the scalp rather than patchy bald spots.
Low ferritin is a commonly overlooked contributing factor. Hair loss continues in women with ferritin below 70 to 100, even though standard labs call lower values normal. Thyroid dysfunction and elevated cortisol are additional drivers that overlap with the menopausal transition.
Hair can grow back with the right intervention. Addressing the hormonal picture, correcting ferritin, and supporting the follicle environment can result in meaningful regrowth over six to twelve months. At Atlas Lifespan, hair loss in women is treated as a systemic hormonal and metabolic problem, not a cosmetic one.
-
Sarcopenia is the age-related loss of skeletal muscle mass and strength. It begins in the mid-30s and accelerates significantly after 50. By age 70, many people have lost 30 to 40 percent of their peak muscle mass without actively working to preserve it.
The consequences extend well beyond appearance. Muscle is metabolically active tissue. Its decline is associated with insulin resistance, increased cardiovascular risk, cognitive decline, bone loss, and a dramatically higher risk of falls and fractures in later life.
The primary hormonal drivers are declining testosterone in men, declining estrogen in women, declining growth hormone across both sexes, and increasing cortisol with age. Protein intake and resistance exercise are the most powerful behavioral interventions, but they work best when the hormonal environment supports muscle synthesis. At Atlas Lifespan, patients on hormonal optimization protocols consistently see improvements in lean mass alongside the other benefits of treatment.
-
Standard annual physicals are designed to catch disease, not measure how well you are aging. A meaningful longevity assessment requires a different set of markers.
Hormonal: Testosterone, estradiol, DHEA-S, full thyroid panel including reverse T3 and antibodies, and fasting insulin
Metabolic: Fasting glucose, HbA1c, and a full lipid panel including ApoB, Lp(a), and LDL particle number. Standard cholesterol panels miss most of the relevant cardiovascular risk information.
Inflammatory: hs-CRP, homocysteine, and ferritin. Chronic low-grade inflammation is a primary driver of accelerated aging.
Cellular health: IGF-1, Vitamin D, RBC magnesium, omega-3 index, and uric acid.
At Atlas Lifespan, our initial comprehensive panel covers the most clinically actionable markers across all of
these categories. We review everything together to identify the highest-leverage interventions. -
The evidence is increasingly compelling, particularly for women who start hormone therapy during the perimenopausal window. Estrogen supports blood flow to the brain, stimulates neuronal growth and repair, reduces amyloid-beta accumulation associated with Alzheimer’s pathology, and regulates the cholinergic system that governs memory and learning.
The KEEPS cognitive and affective study found that women who started transdermal estradiol early in the menopausal transition performed better on verbal learning and memory tests. The SWAN study and other longitudinal research show that starting HRT during perimenopause or within a few years of the final menstrual period appears to be protective
At Atlas Lifespan, we discuss the full long-term picture with every patient making decisions about hormone therapy. The conversation is never just about hot flashes.
-
Sleep and hormones are bidirectionally connected. Disrupted sleep alters hormone levels, and hormonal imbalance disrupts sleep. For most people dealing with fatigue, weight changes, cognitive fog, and mood shifts, both are happening at the same time.
Growth hormone is released primarily during deep slow-wave sleep. Poor sleep significantly reduces output, accelerating muscle loss, fat gain, and cellular repair deficits. Cortisol follows a natural rhythm that chronic sleep disruption flattens, keeping cortisol elevated at night when it should be low. Elevated nighttime cortisol breaks down muscle, promotes visceral fat storage, drives insulin resistance, and suppresses testosterone and estrogen.
For women in perimenopause and menopause, night sweats and hot flashes create a cascade where poor sleep raises cortisol, which further suppresses estrogen and progesterone, which worsens sleep. Breaking that cycle requires addressing the hormonal root cause. At Atlas Lifespan, sleep disruption is treated as part of the hormonal picture, not as a separate problem.